LOGIN  |  REGISTER
Chimerix

Ceribell to Report Third Quarter 2024 Financial Results on November 12, 2024

October 29, 2024 | Last Trade: US$ 26.53 0.00 0.00

SUNNYVALE, Calif., Oct. 29, 2024 /PRNewswire/ -- Ceribell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 12, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7168007. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/

About Ceribell Inc.

Ceribell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Ceribell System is an AI-powered, rapidly deployable point-of-care electroencephalography ("EEG") platform designed to address the unmet needs of patients in the acute care setting. The company is headquartered in Sunnyvale, Calif.

Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Corrie Rose
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB